National Institutes of Health: all 11,571 studies

Page 35 of 116. Open to participants first (946), then studies with results posted, then the rest; newest registration first within each.

• A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal CancerWithdrawnNCT06410534Phase 2
• Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)WithdrawnNCT06400264Phase 2
• Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)Active, not recruitingNCT06400225Phase 2
• Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian CancerWithdrawnNCT06393751Phase 1/2
• Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)Active, not recruitingNCT06390865Phase 2
• Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)Active, not recruitingNCT06385496Phase 2
• CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in PregnancyWithdrawnNCT06336434Phase 1/2
• Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.Active, not recruitingNCT06332339Phase 1
• Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent GlioblastomaWithdrawnNCT06328036Phase 2
• Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent GlioblastomaSuspendedNCT06325683Phase 2
• Venetoclax for the Treatment of Patients With Relapsed Hairy Cell LeukemiaActive, not recruitingNCT06311227Phase 2
• Care Choreographies and the Making of the Psychosocial in Genetic CounselingCompletedNCT06280833
• GS-441524 for COVID-19 SAD, FE, and MAD Study in Healthy SubjectsWithdrawnNCT06274853Phase 1
• A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + AlumWithdrawnNCT06267872Phase 1
• Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerActive, not recruitingNCT06253520Phase 1
• A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or LupusWithdrawnNCT06238531Phase 1
• Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use DisorderActive, not recruitingNCT06233799Phase 3
• Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)WithdrawnNCT06210750Phase 2
• Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple MyelomaSuspendedNCT06179888Phase 2
• Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple MyelomaActive, not recruitingNCT06169215Phase 2
• Pilot Study of Isocaloric Time Restricted Eating on Ketone Metabolism and ImmunoregulationCompletedNCT06169137Not applicable
• Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsActive, not recruitingNCT06169124Phase 2
• Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid TumorsWithdrawnNCT06161558Phase 1
• Investigation of Immune Amnesia Following Measles Infection in Select African RegionsCompletedNCT06153979
• Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal InfectionsActive, not recruitingNCT06126263
• A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital CytomegalovirusCompletedNCT06118515Phase 1
• VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis BActive, not recruitingNCT06092333Phase 2
• Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1SuspendedNCT06071767Phase 1/2
• Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before SurgerySuspendedNCT06050252Phase 2
• A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIVCompletedNCT06033209Phase 1
• Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in AdultsCompletedNCT06026514Phase 1
• Semaglutide Therapy for Alcohol Reduction (STAR)Active, not recruitingNCT06015893Phase 2
• Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in FirefightersActive, not recruitingNCT06009926Phase 2
• The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage AntibodiesActive, not recruitingNCT06006546Phase 1
• Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute LeukemiasCompletedNCT05969002
• Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy AdultsCompletedNCT05968989Phase 1
• Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment TrialWithdrawnNCT05967286Phase 2
• Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta HepatitisWithdrawnNCT05953545Phase 2
• Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX TrialActive, not recruitingNCT05947500Phase 2
• A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy AdultsCompletedNCT05945485Phase 1
• Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive AdultsCompletedNCT05913973Phase 1
• A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) RecipientsCompletedNCT05909202Not applicable
• Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal CancerSuspendedNCT05904080Phase 2
• Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIVActive, not recruitingNCT05903339Phase 1
• Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal CancerWithdrawnNCT05898828Phase 1/2
• Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERASWithdrawnNCT05879484Phase 1/2
• Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided BiopsyTerminatedNCT05872503
• Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following TreatmentActive, not recruitingNCT05859334Phase 2
• To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIVCompletedNCT05854381Phase 1
• A Study of Doxycycline to Treat Chlamydial InfectionCompletedNCT05840159Phase 4
• Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) CancerActive, not recruitingNCT05836584Phase 2
• Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate CancerActive, not recruitingNCT05828082Phase 2
• Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA MutationsWithdrawnNCT05807126Phase 1
• Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)Active, not recruitingNCT05797246Phase 2
• Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell MalignanciesActive, not recruitingNCT05797233Phase 1
• A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy AdultsCompletedNCT05755620Phase 1
• Procedural Motor Memory in Long COVID-19CompletedNCT05746624
• Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)Active, not recruitingNCT05743244Phase 2
• Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine TumorsActive, not recruitingNCT05724108Phase 2
• A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin LymphomaWithdrawnNCT05711628Phase 3
• Resiniferatoxin for the Management of Refractory Morton s Neuroma PainCompletedNCT05695339Phase 1
• Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersActive, not recruitingNCT05691504Phase 1
• A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed OsteosarcomaSuspendedNCT05691478Phase 2/3
• CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic CancerSuspendedNCT05685602Phase 1
• Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative PersonsCompletedNCT05683834Phase 1/2
• Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell DiseaseActive, not recruitingNCT05675436
• Imaging Characterization of the Biomechanical Coupling of Brain and SkullWithdrawnNCT05675423
• Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast CancerSuspendedNCT05673200Phase 1
• Adolescent Vaping Characterization and Parent Views on Adolescent Vaping ProtocolTerminatedNCT05669716
• Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver DiseaseCompletedNCT05669677
• Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland CancersActive, not recruitingNCT05669664Phase 2
• A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal HyperplasiaWithdrawnNCT05663320Not applicable
• Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)WithdrawnNCT05652504Phase 1
• The Role of Gut Microbiome in Predicting Comorbidities and Complications in Children With Inflammatory Bowel DiseaseWithdrawnNCT05652491
• Transcranial Magnetic Stimulation for Youth With Treatment-Resistant Major Depressive DisorderWithdrawnNCT05652465Phase 2
• Functional Near-Infrared Spectroscopy (fNIRS) Combined With Diffuse Correlation Spectroscopy (DCS) in Neurocognitive Disease as Compared to Healthy Neurotypical ControlsCompletedNCT05642221
• Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung CancerSuspendedNCT05642195Phase 1/2
• Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)Active, not recruitingNCT05638295Phase 2
• Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted TreatmentActive, not recruitingNCT05627245Phase 1
• Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)CompletedNCT05621304
• A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral TherapyActive, not recruitingNCT05612178Phase 1
• Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell TransplantActive, not recruitingNCT05605574Not applicable
• Exploring Near Infrared Spectroscopy (NIRS) Technologies for Assessment of Muscle Physiology, Tissue Oxygenation, and Blood Flow in Patients With Sickle Cell Disease (SCD)CompletedNCT05604547
• Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)Active, not recruitingNCT05600907Early Phase 1
• Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative NeoplasmActive, not recruitingNCT05600894Phase 2
• Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant TuberculosisCompletedNCT05586230Phase 1
• A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 InfectionWithdrawnNCT05582694Phase 2
• Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA TrialWithdrawnNCT05564416Phase 2
• Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)Active, not recruitingNCT05564403Phase 2
• Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment TrialActive, not recruitingNCT05554380Phase 2
• Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554367Phase 2
• Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment TrialActive, not recruitingNCT05554341Phase 2
• Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554328Phase 2
• Speckle Plethysmography Pulse Transit Time as a Marker of Blood Pressure ChangesCompletedNCT05554315
• Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIVCompletedNCT05551273Phase 2
• Implications of Maternal 45,X Mosaicism as a Secondary Genomic Finding Following Cell-Free DNA Sequencing During Pregnancy: A Deep Phenotype StudyWithdrawnNCT05548881
• Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial CancersActive, not recruitingNCT05538897Phase 1/2
• Adolescents Seeking COVID Vaccination (Teen COVID Vax)CompletedNCT05537103
• Study of Pregnancy And Neonatal Health (SPAN)TerminatedNCT05515744Not applicable
• Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated CytopeniasWithdrawnNCT05509582Phase 2

← National Institutes of Health overview and focus areas